Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
UroGen Pharma
UroGen Pharma
(URGN)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Jelmyto
Mitomycin
2020-04-15
2026-2031
Colorectal neoplasms
,
Pancreatic neoplasms
,
Stomach neoplasms
,
Urinary bladder neoplasms
,
Adenocarcinoma
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Mitomycin
urinary bladder neoplasms
,
invasive hydatidiform mole
ZALIFRELIMAB
glioma
,
diffuse intrinsic pontine glioma
,
urologic neoplasms
,
carcinoma
,
non-muscle invasive bladder neoplasms
,
uterine cervical neoplasms
,
urinary bladder neoplasms
,
sarcoma
,
non-small-cell lung carcinoma
,
pancreatic ductal carcinoma
,
hemangiosarcoma
,
prostatic neoplasms
,
pancreatic neoplasms
,
squamous cell carcinoma of head and neck
,
neoplasms
Mephedrone
non-hodgkin lymphoma
,
large b-cell lymphoma diffuse
,
b-cell lymphoma
,
burkitt lymphoma
Azzalure
psoriasis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use